Key result
Radiofrequency renal denervation is linked to ~12-mmHg lower systolic BP at 24 months.
Why the study?
The study aimed to evaluate the medium- and long-term outcomes of renal denervation in patients with resistant hypertension, focusing on blood pressure control, antihypertensive drug burden, and renal safety.
Observational (n=51)
Answers are grounded in this paper and cite their sources.
RD may aid BP control in RH; leaves open long-term efficacy, safety, and renal effects pending RCTs.
OBJECTIVE: To evaluate the medium- and long-term outcomes of renal denervation (RD) in patients with resistant hypertension (RH), focusing on blood pressure (BP) control, antihypertensive drug burden, and renal safety. METHODS: Prospective observational study including 51 patients with RH treated between 2020 and 2024 with radiofrequency RD using the Symplicity Spyral™ system. BP values, antihypertensive therapy, estimated glomerular filtration rate (eGFR), and procedural complications were assessed over a 24-month follow-up. RESULTS: Systolic BP was significantly reduced, with a mean overall decrease of -12.3 mmHg at the end of follow-up (p < 0.001), while diastolic BP decreased by -5.1 mmHg at 24 months (p = 0.01). The number of antihypertensive drugs was significantly reduced, and 82.6% of patients achieved clinical success. A mild decline in eGFR was observed without clinical relevance. Age ≥50 years was associated with a higher likelihood of response. Major complications were infrequent (4.3%). CONCLUSIONS: RD is an effective and safe therapeutic option for selected patients with RH, providing sustained BP reduction and a decreased need for antihypertensive medication.
No takes yet. Share an insight, caveat, or question.
Bustos-Merlo et al. (2026) conducted an observational in Resistant hypertension (n=51). Radiofrequency renal denervation (Symplicity Spyral™ system) was evaluated on Systolic blood pressure reduction at 24 months (MD -12.3 mmHg, p=<0.001). Radiofrequency renal denervation reduced systolic BP by -12.3 mmHg and diastolic BP by -5.1 mmHg at 24 months, with 82.6% clinical success.
Synapse has enriched 10 related papers. Consider them for comparative context: